Capricor Therapeutics (NASDAQ:CAPR) Stock Price Crosses Above Fifty Day Moving Average of $5.56

Capricor Therapeutics Inc (NASDAQ:CAPR)’s share price passed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $5.56 and traded as high as $5.65. Capricor Therapeutics shares last traded at $5.04, with a volume of 912,876 shares.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on CAPR. Cantor Fitzgerald started coverage on Capricor Therapeutics in a report on Friday, January 5th. They set an “overweight” rating and a $8.00 price target on the stock. StockNews.com raised shares of Capricor Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, January 24th. Finally, HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of Capricor Therapeutics in a report on Friday, March 1st.

Capricor Therapeutics Stock Up 4.6 %

The company has a market cap of $158.78 million, a P/E ratio of -5.79 and a beta of 3.99. The company has a fifty day moving average of $5.56 and a 200 day moving average of $4.34.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings results on Thursday, February 29th. The biotechnology company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.21. The firm had revenue of $12.09 million during the quarter, compared to analyst estimates of $5.80 million. Capricor Therapeutics had a negative net margin of 88.52% and a negative return on equity of 299.67%. As a group, research analysts forecast that Capricor Therapeutics Inc will post -0.83 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Capricor Therapeutics stock. Citigroup Inc. purchased a new stake in shares of Capricor Therapeutics Inc (NASDAQ:CAPR) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 61,591 shares of the biotechnology company’s stock, valued at approximately $211,000. Citigroup Inc. owned 0.20% of Capricor Therapeutics as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.